Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today reported financial results for ...

NoviThera is developing a novel anti Monoclonal anti Body treatment. The invention was made by Allan Wehnert, CEO of NoviThera in conjunction with Nordicus. NoviThera’s mission is to research and ...

For adults and adolescents with moderate-to-severe plaque psoriasis, selective blockade of the interleukin-23 receptor with ...

Discover key truths about psoriasis, from symptoms and causes to effective management strategies to improve your quality of ...

A novel oral therapy that inhibits the interleukin-23 inflammatory pathway provided control of moderate-to-severe psoriasis ...

A cognitive behavioral therapy program delivered by smartphone app improved the mental health and quality of life of people ...

Following the NDA submission for icotrokinra treatment of adults and adolescents with moderate to severe plaque psoriasis to ...

Significant rates of depression, anxiety, and sleep disturbances in patients with psoriatic arthritis (PsA) and palmoplantar psoriasis (PPP) were identified, underscoring the need for integrated ...

The novel, oral interleukin-23 inhibitor icotrokinra bested placebo in multiple skin outcomes among adolescent patients with ...

Hispanic adults with psoriasis receive biologics far less often than non-Hispanic White adults, despite having more prescriptions and more dermatologist visits.